Latest research on solifenacin succinate

Solifenacin (rINN), marketed as solifenacin succinate under the trade name Vesicare, is a urinary antispasmodic of the anticholinergic class. It is used in the treatment of overactive bladder with urge incontinence. [Wikipedia]

solifenacin succinate indications

A 4-week course of solifenacin succinate treatment in women with OAB seemed to have no clinically significant effect on intraocular pressure, but further larger studies are needed to determine the effect of anticholinergics on anterior chamber parameters and to evaluate their safety in glaucoma patients [61, 62]. [source, 2014]
Indication of additional administration of solifenacin succinate was clinically decided based on experience of each urologist by concerning comorbidity, maximum flow rate (Qmax), postvoid residual urine volume (PVR), and so forth to minimize development of acute urinary retention. [source, 2010]